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Hepatitis C virus (HCV) is the agent responsible for 
posttransfusion hepatitis. The incidence, timing, 
and clinical course of HCV positive hepatitis in 
liver transplant recipients are unknown. Three 
hundred and seventeen donor-recipient liver trans-
plant pairs were grouped on the basis of their pre-
transplant HCV antibody status. The biopsy find-
ings were examined. Four distinct groups were 
identified on the basis of HCV serology: group I, 
both were negative; group II, donor was negative 
and recipient was positive; group III, donor was pos-
itive and recipient was negative; group IV, both 
were positive. The prevalence of anti-HCV positiv-
ity in recipients was 13.6%. The rate of seroconver-
sion was 9.2%. Histologic hepatitis not ascribable to 
any specific cause other than non-A, non-B (NANB) 
hepatitis occurred in 13.8%. The incidence of his to-
logic chronic active hepatitis was 1.6%, and none 
progressed to cirrhosis. The concordance rate for a 
positive anti-HCV serology and NANB hepatitis 
was 2.8%. Of the 35 patients (group II and IV) with 
positive anti-Hey serology pretransplant, only 17 
were positive posttransplantation. Based on these 
data it can be concluded that posttransplant NANB 
hepatitis occurred in 13.8% of liver recipients. 
Twenty percent of these were anti-HCV positive. 
Progression to histologic chronic active hepatitis 
occurs over a period of 1-5 years in 1.6% of cases. 
T he hepatitis C virus (HCV) has been identified as the principal etiologic agent responsible for 
posttransfusion hepatitis. 1 An assay for anti-HCV an-
tibody using the enzyme-linked immunosorbent as-
say (ELISA) technique was developed in 1989 by 
Chiron Corporation. 1.2 This test has been shown to be 
both accurate and reproducible although some false 
positive tests occur particularly in patients with hy-
pergammaglobulinemia. 3.4 As a result, newer confir-
matory tests using molecular biology techniques 
have been developed. 5 ·With the availability of the 
original test and occasionally also the newer confir-
matory tests, several studies have been performed 
defining the incidence and prevalence of hepatitis C 
antibody in blood donors and in recipients of blood 
transfusions as well as in patients with various 
chronic liver diseases.6- 10 These studies have shown 
that as many as 20%-50% of patients with advanced 
chronic liver disease are anti-HCV positive. Few 
studies have been performed in patients being con-
sidered for or having a liver transplant. 11•12 
The present study was designed to answer the fol-
lowing questions that are unique to a liver transplant 
population: (a) What is the effect of an organ donor's 
HCV serologic status on the recipient's posttrans-
plant clinical course and Hev serology? (b) What is 
the incidence, timing, and clinical course of anti-
HeV positive hepatitis in liver transplant recipients? 
(c) Should donor organs be rejected for consideration 
for transplantation if the donor is found to be anti-
HCV positive? 
Materials and Methods 
Data on all patients who received a single orthoto-
pic liver transplant (OLTx) at the Presbyterian University 
Hospital, Pittsburgh, Pennsylvania, between March 1986 
and March 1990 were reviewed (n = 568). Only those recip-
ients for whom both donor and recipient pretransplant and 
posttransplant serum were available were included in this 
study (n = 317). When pre transplant parameters such as 
age, gender disease, and United Network for organ sharing 
score were compared between patients meeting these crite-
ria and those that did not, no statistical differences were 
seen between the subj ects of this study and those rej ected 
from study because of an absence of sera (Table 1). 
All patients received Cyclosporine A and prednisone as 
the primary immunosuppressive agents. Rejection epi-
sodes were treated with bolus (1-g doses) of methylpredni-
solone or a recycle of prednisone decreasing daily by 40 mg 
from an initial starting dose of 200 mg. Steroid-resistant 
rej ection was treated with a 5-10 day course of the mono-
clonal antibody OKT3. 
In general. a diagnosis of viral hepatitis was associated 
with a 20%-25% reduction in the dose of cyclosporine be-
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Table 1. Characteristics and Specific Diseases of Liver 
Transplant Patients Included and Excluded From 
the Study Because of Inadequate per~ 
Recipients 
Not 
included Included 
Demographics 
n 251 317 
age (yr) 45.7 ± 0.8 45.9 ± 0.5 NS 
Sex 
M(%) 142 (56.6) 169 (53.3) NS 
F(%) 109 (43.4) 148 (46.7) NS 
Biochemical parameters 
Albumin (g/ dL) 2.9 ± 0.1 2.9 ± 0.1 NS 
Protime (s) 15.8 ± 0.3 16.1 ± 0.7 NS 
Total Bilirubin (mg/dL) 9.4 ± 0.7 8.4 ± 0.5 NS 
Specific liver disease Total 
Acute hepatic necrosis 10 12 22 
Post necrotic cirrhosis 151 159 310 
Secondary biliary cirrhosis 4 5 9 
PBS or PSC 47 87 134 
Metabolic liver disease 14 17 31 
Budd-Chiari syndrome 2 7 9 
Tumors 22 29 51 
Others 1 1 2 
Totals 251 317 568 
ing used. Otherwise, no specific alterations in the immuno-
suppressive regimen was associated with such a diagnosis. 
All sera were stored at -70 o e before being tested for 
anti-He V antibody. The posttransplantation serologic de-
termination was made on the last available serum sample, 
which was obtained at 18.6 ± 0.65 months post OL Tx 
(range, 1-50 months). 
The anti-Hey procedure used was an enzyme-linked 
assay from Ortho Diagnostics (Raritan, NT). The test was 
performed following the procedures recommended by the 
manufacturer. All specimens found to have an absorbance 
level less than the cut-off value were considered negative. 
All specimens with an absorbance level greater than the 
cut-off value were rerun in duplicate to confirm their posi-
tivity. If the sample was consistently positive. it was iden-
tified as being positive. Those that were reassayed but fell 
below the cut-off value were considered negative. The 
cut-off value was determined by the mean value of known 
negative controls plus 0.400 absorbance units. When the 
RIB A-II assay (Grtho Diagnostics, Raritan, New Jersey) be-
came available, all samples for both the donors and the 
recipients were reassayed with this assay system. The re-
sults confirmed the results obtained with the original 
ELISA System in >91 % of the cases. 
All donor charts were reviewed for the latest available 
laboratory values of serum alanine aminotransferase 
(AL TJ, prothrombin time (PT), and total bilirubin before 
organ donation. ALT values >40 Karmen U/mL, aPT >13 
seconds, and total serum bilirubin >1.0 mg/dL were con-
sidered to be abnormal values. 
A total 86.4% of the recipients had a liver biopsy per-
formed sometime during their follow up posttransplant 
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care for a specific clinical indication. In general, liver biop-
sies were performed if either the bilirubin level increased 
by >25% and biliary obstruction could be ruled out on the 
basis of the absence of intrahepatic bile duct dilation or an 
increase in the serum level of either the alanine or aspar-
tate aminotransferase level of >25%. All liver biopsies 
were read by a single staff pathologist at the Presbyterian 
University Hospital and rereviewed by the authors and 
graded using the Knodell criteria.13 A histological diagno-
sis of non-A, non-B (NANB) hepatitis was made when the 
serum aminotransferase levels were increased and histo-
logic evidence for hepatitis consisting of liver cell necrosis, 
Kupffer cell hyperplasia, and a portal inflammatory infil-
trate were present in the absence of histology and serologic 
evidence for hepatitis A, B, D, cytomegalovirus. Epstein-
Barr virus, and herpes simplex virus infection or rejection. 
Thirty-one of 44 (70.4%) recipients with a posttransplant 
diagnosis of putative NANB hepatitis (whether anti-Hey 
positive or negative) had one or more liver biopsies during 
the posttransplant follow-up period. These were reviewed 
to determine the rate of progression of the histologic liver 
disease to chronic active hepatitis (eAH) and cirrhosis. 
Statistical Analysis 
All data are reported as mean values ± SEM. The 
Students' t test was used to compare mean values between 
groups. Survival curves were prepared according to the 
method of Kaplan and Meir.14 A P value <0.05 was consid-
ered significant. 
Results 
All 317 recipients could be grouped into one 
or another of four categories based on the serologic 
status of their pre-OL Tx serum and that of their do-
nor for anti-HCV (Table 2). 
The ages of recipients ranged from 16 to 68 years 
(45.9 ± 0.5 years). There were no differences be-
tween the four groups for age. There were 169 male 
and 148 female recipients. Again. no differences in 
distribution between the four groups was evident 
based on gender. Based on clinical criteria, none of 
the recipients who were anti-HCV positive before 
transplantation were thought to have acute hepati-
tis. 
Of the 317 donors. only 244 (77.9%) had complete 
biochemical data (ALT, PT. and total bilirubin) avail-
Table 2. HeV Serology of the 317 Donor-Recipient Pairs at 
the Time of Transplantation 
Anti-HCV antibody status 
Group n Donor Recipient 
273 Negative :--J egati ve 
II 34 Negative Positive 
!II 9 Positive Negative 
IV Positive Positive 
, 
'. 
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able at the time of organ donation. Sixty-three 
(19.9%) had one or more missing data points. Seven 
(2.2%) had no data at all. Each of these donors with-
out any laboratory data assessing liver injury and/or 
function were in group 1. No evidence of pre-existing 
histologic liver disease was evident in any of the do-
nors for whom liver biopsies were obtained before 
actual organ engraftment (n = 56). 
Twenty-six of 282 (9.2%) recipients in group I and 
group III combined who had a negative HCV serology 
before the OL Tx became anti-HCV positive follow-
ing OL Tx at a time interval ranging between 2-45 
months (mean 18.9 ± 2.38 months) since the date of 
the transplant. Twenty-five ofthese were from group 
I (negative donor to negative recipient) while only 1 
was from group III (positive donor to negative recipi-
ent) (Table 3). 
Thirty-five recipients in group II and group IV who 
were seropositive for anti-HCV before OLTx were 
followed for 6-44 months (mean 22.0 ± 1.88 months) 
and only 17 (48.6%) persisted in having a positive 
anti-HCV at the time oflast follow up (Table 3). Sev-
enteen of the 34 patients from group II who were 
found to be seronegative for anti-HCV post-OLTx 
were evaluated further. Charts were reviewed to ob-
tain data on y globulin levels before transplantation 
to rule out the possibility of hypergammaglobulin-
emia causing false positive serology for anti-HCV. 
These 17 patients had mean y globulin levels of 
3.01 ± 0.16 and ELISA ratio with a mean level of 
1.6 ± 0.18 pre-OLTx. Four recipients had low ELISA 
ratios (1.01, 1.09, 1.08, and 1.11; mean 1.07 ± 0.02). 
The remaining 13 recipients had ELISA ratio with a 
mean level of 1.79 ± 0.21. The 4 recipients with a low 
ELISA ratio had a mean y globulin level of 3.18 ± 
0.42, whereas the 13 recipients with an increased 
ELISA ratio had a mean y globulin level of 2.95 ± 
0.16. These data suggest that the 17 recipients from 
group II who became seronegative post-OLTx were 
unlikely to have had an initial false positive HCV 
serology pre-OL Tx as a result of having hypergam-
maglobulinemia. 
HCV AND OL Tx 325 
Of the 274 recipients who had a liver biopsy per-
formed sometime during their follow up, 78.8% 
(216/274) had more than 1 liver biopsy. A total of935 
liver biopsies were performed in these 274 recipients 
(average 3.4 per recipient) (Table 4). Thirty-nine of 
the 43 recipients with a positive HCV serology follow-
ing OL Tx had a liver biopsy. An average of 4 liver 
biopsies per such recipient were obtained. Four re-
cipients never had a liver biopsy obtained during 
their follow up because no clinical indication for a 
biopsy was ever present. 
Histological evidence of putative NANB hepatitis 
was found in 13.8% (44/317) ofthe recipients. These 
44 recipients had an average of 5.4 liver biopsies 
each (Table 4). Thirty-four (77.3%) of these recipi-
ents were in group 1. 7 (15.9%) were in group II. 3 
(6.8%) were in group III. The time interval from 
OL Tx to first histological evidence of putati ve NANB 
hepatitis ranged from 1-27 months with the mean 
being 9.6 ± 1.15 months (Table 5). 
Only 9 (2.8%) recipients had both a positive HCV 
serology and a histologic evidence of putative NANB 
hepatitis. Five of these were from group I and 4 were 
from group II (Table 4). Thirty-five (79.5%) of recipi-
ents with histological evidence of putative NANB 
hepatitis post-OLTx were anti-HCV negative (Table 
5). Conversely, 79% of the recipients with a positive 
HCV serology post-OLTx never had any histological 
evidence for NANB hepatitis post-OLTx (Table 6). 
Only 1.6% of the 317 recipients developed histo-
logic CAH post-OLTx. Four of these were from group 
I and 1 was from group II. None have developed cir-
rhosis. All five of those who developed CAH were 
seronegative for antibody post-OLTx. The time in-
terval from OLTx to first evidence of CAH was 1-27 
months (mean 13.2 ± 4.7 months). The Knodell 
scores for these 5 subjects ranged from 13-17 with 
the severity of the periportal and bridging necrosis 
component of the score contributing most to the 
overall score (Table 7). 
The survival was best for those in group III (posi-
tive donor into a negative recipient) with 100% sur-
Table 3. The Frequency and Timing of Hev Positivity in the 317 Recipients Studied 
No. with positive 
Groups HCV serology (%)0 
I(n = 273) 25 (9.2) 
II (n = 34) 17 (50) 
III (n = 9) 1 (11.1) 
IV (n = 1) 0(0) 
Totals (n = 317) 43 (13.6) 
~AK not available. 
'"Determined at last follow up. 
Interval for recipient with 
positive HeV serology 
[rna (mean ± SEM)]b 
2-45 (19.2 ± 2.46) 
6-36 (20.2 ± 2.46) 
12 
NA 
2-45 (19.4 ± 1.72) 
bInterval from OLTx to last available serum sample of recipient. 
Interval for recipient with Interval for all 
negative HeV serology recipients 
[rna (mean ± SEM)]b [rna (mean ± SEMllb 
1-50 (17.6 ± 0.73) 1-50 (17.8 ± 0.70) 
6-42 (22.4 ± 2.73) 6-42 (21.3 :': 1.82) 
5-37 (19.5 ± 4.4) 5-37 (18.6 ± 4.01) 
44 44 
1-50 (18.1 ± 0.71) 1-50 (18.6 ± 0.65) 
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Table 4. Number of Liver Biopsies Performed on the Recipients of Each Group Separated as to the Presence of Positive 
HeV Serology, Positive Histology, or Both 
No. with 
No. with positive 
LEx Total LEx HCV serology 
Groups post-OLTx (avg/pt) post-OLTx 
I (n = 273)" 237 797 (3.4)b 25 
II (n = 34)C 29 101 (3.5) 17 
IIl(n=9) 8 37 (4.6) 1 
IV (n = 1) 0 0 0 
Totalsd 274 935 (3.4) 43 
LBx, liver biopsy. 
aOne recipient did not have a liver biopsy. 
bMean number of liver biopsies per patient. 
cTwo recipients did not have a liver biopsy. 
dFour recipients did not have a liver biopsy. 
Total LBx 
(avg/pt) 
97 (4) 
61 (4) 
1 (1J 
0 
159 (4) 
viving through 4 years. The survival of those in 
group II (negative donor into positive recipient) at 4 
years was 94%, which did not differ from that in 
group I where the survival was 89% at 4 years. It is 
not possible to calculate a survival curve for the sin-
gle patient in group IV, but this single patient is still 
alive at 4 years. Thus, the overall survival of all 
groups was excellent ranging between 89 and 100% 
at 4 years. 
Graft survival was also calculated for each group. 
The graft survival at 4 years for those in group I was 
87%, whereas it was 94% for those in group II and 
100% for those in group III and IV. Again, because of 
the overall excellence in results, no statistical differ-
ences exist among the 4 groups for graft survival. 
Discussion 
Several important observations can be made 
from this study. First, the incidence of anti-Hey posi-
tivity following transplantation was found to be 
13.6% in liver recipients at the time oflast follow up. 
The incidence of histological NANB hepatitis was 
quite similar, being 13.8% with a follow-up period of 
1-27 months (mean 9.6 months). However, the con-
No. with 
histologic 
NANB hepatitis 
post-OLTx 
34 
7 
3 
o 
44 
Total LBx 
(avg/pt) 
190 (5.6) 
31 (4.4) 
18 (6) 
o 
239 (5.4) 
No. with histologic 
NANB hepatitis and 
positive HCV 
serology post-OL Tx 
5 
4 
o 
o 
9 
Total LBx 
(avg/ptJ 
28 (5.6J 
19 (4.7) 
o 
o 
47 (5.2) 
cordance of an HeV positive serology and histologic 
hepatitis was quite low, being only 2.8%. A highly 
likely possibility for this finding is that the identifi-
cation of HCV infection among transplanted patients 
with current anti-Hey assay techniques grossly un-
derestimates the magnitude of the problem. The use 
of peR techniques to detect HCV-RNA in serum and 
tissue not yet available to the current investigators 
should rectify this problem. 
Hemophiliacs have an anti-Hey positivity rate of 
40%-70% because of their frequent and repetitive 
exposure to blood and blood products. 1S,16 Patients 
with OL Tx also have a high exposure to a variety of 
blood products and might be considered to be at in-
creased high risk for posttransfusion NANB hepati-
tis. However, the actual incidence ofNANB hepatitis 
found in the liver transplant population was remark-
ably lower than that reported for hemophiliacs. 
Only 2.8% (9/317) patients had histological evi-
dence of NANB hepatitis as well as being anti-Hey 
positive at the time oflast follow up post-OL Tx. Thus 
there was little concordance between the serologic 
status of the recipient and the histologic findings of 
NANB hepatitis post-OLTx. This is unlike the 60%-
Table 5. Frequency. Timing. and Severity of the Posttransplant Hepatitis in the 4 Groups Studied 
No. with histologic 
No. with histologic NANB hepatitis and Time interval for 
NANB hepatitis negative HCV serology No. with CAH NANB hepatitis 
Groups post-OLTx (%) post-OL Tx (%) post-OL Tx (%) [range (mean; mol]" 
T(n=273J 34 (12.4J 29 (10.6) 4 (1.5J . 1-27 (9.5) 
II (n = 34) 7 (20.6) 3 (8.8) 1 (2.9) 1-27 (11.0) 
III[n=9} 3 (33.3) 3 (33.3) 0 5-15 (9.3) 
IV (n = 1) 0 0 C 0 
Totals (n = 317) 44 (13.8) 35 (11.0) 5 (1.6) 1-27 (9.6) 
"Interval from OL Tx to first histologic evidence. 
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Table 6. Frequency of Pasttransplant Hepatitis in the 317 Recipients Studied Separated as to Positive HCV Serology and 
Histology 
No. post-OL Tx No. with histologic NANB No. with no histologic NANB 
Groups (% ) hepatitis post-OL Tx (%) hepatitis post-OL Tx [%) 
I (n = 273) 25 (9.15) 
II (n = 34) 17 [50) 
III (n = 9) 1 [11.1) 
[V (n = 1) 0 
Totals (n = 317) 43 (13.6] 
100% concordance rate found in cases of posttrans-
fusion hepatitis as reported by Alter et a1. using the 
same techniques as in the present report. 17 
As noted above, the application ofFCR techniques 
to detect HCV -RNA in serum and tissue in future 
studies should improve on the present findings. The 
prevalence of seroconversion from anti-Hey nega-
tive to anti-HCV positive was found to be 9.2% (26/ 
282, groups I and III) in this population. This is com-
parable to the seroconversion rate of individuals 
receiving one or more transfusions reported by Este-
ban et a1. 18 Overall, the incidence of posttransfusion 
hepatitis has been found to range from 2%-15% in 
several different studies from various countries. 19- 23 
The results of this study suggest that the blood trans-
fusions given before, during, and after the liver 
transplant procedure were more likely to be the 
source of NANB hepatitis in the recipients who de-
veloped hepatitis than was the donor organ. When 
all blood units are tested for the presence of HCV 
before transfusion, the incidence of NANB hepatitis 
post-OLTx may be reduced. 24- z6 
An interesting observation was made in group II. 
Specifically, 17 (50%) of the surviving recipients 
were anti-Hey antibody positive at the time of last 
follow up although a1134 had been anti-HCV positive 
before their transplant. The reason for the disappear-
ance of Hev antibody in 50% of these patients is 
unclear. Whether this reflects an effect of the immu-
nosuppression used, insensitivity of the assay, a 
unique characteristic of this population, or some 
other cause is as yet unclear. The possibility of false 
positivity of anti-HCV secondary to hypergamma-
Table 7. Knodell Scores for the 5 Recipients With CAH 
Periportal Intralobular 
positive /negative degeneration and 
No. bridging necrosis focal necrosis 
1 6 
2 6 4 
3 .. 3 
4 4 3 
5 5 3 
5 (1.8) 20 [7.3) 
4 (11.8) 13 [38.2) 
0 1 (11.1) 
a 0 
9 (2.8) 34 (10.7) 
globulinemia was eliminated by obtaining, calculat-
ing, and comparing total y globulin levels and ELISA 
ratios and finally by confirming the results obtained 
with the Ortho Diagnostic assay with those obtained 
using the more recently available RIB A-II assay. 
Overall, a concordance rate of 91% was seen be-
tween the ELISA procedure and the RIBA-2 assay in 
this study population. 27 However, a similar observa-
tion has been made after liver transplantation by 
Trainer et a1. and Grendele et al,28.29 However, the 
number of patients studied by these authors was 
rather small (9 and 6, respectively). They observed a 
rate of 33% for persistence of anti-He V antibody in 
liver recipients who were seropositive before their 
OLTx. These observations suggest that the obligate 
immunosuppression required following OL Tx can 
block the expression of anti-Hey and/or prevent its 
development. 
A very low incidence (1.58%) of CAH was found in 
this unique group of patients after 4 years of follow 
up; none developed cirrhosis. All of those who devel-
oped histologic CAH were anti-HCV negative. 
Eleven percent (5/44) of the recipients with histologi-
cal evidence of NANB hepatitis progressed to CAH. 
This is also lower than the incidence of CAH and 
cirrhosis found in histologically proven cases of post-
transfusion NANB hepatitis as determined by Matt-
son et a1,29 These authors found a 59% incidence of 
CAH, and 46% of their patients showed early cirrho-
sis after a follow-up period of 5 years. 
Ten patients in groups III and IV received livers 
from donors who were seropositive for anti-HCV. 
Only 1 of these recipients (10%) was anti-HCV posi-
Portal 
inflammation Fibrosis Final score 
3 3 13 
.. 3 17 
3 3 13 
3 3 13 
3 4 15 
--------------------
328 SHAH ET AL. 
tive and only 3 (30%) have developed putative 
NANB hepatitis post-OLTx; none have developed 
CAH. Nonetheless, the relatively high incidence of 
NANB hepatitis in 33% of those receiving a liver 
from an anti-HCV positive donor should be noted 
and should suggest caution when using such organs 
except in critical situations and until more data con-
cerning the issue of the progression of NANB hepati-
tis in an allograft recipient is available. 
Both patient and graft survival was excellent 
(87%-100%) in all four groups studied at 4 years. Sur-
prisingly, the best survival rates (100%) were found 
in groups III and IV who received organs from donors 
that were anti-HCV positive. Although the number 
of recipients in groups III and IV combined was small, 
the evidence does not support a policy of rejecting 
scarce organs for transplantation solely because the 
donor is anti-HCV positive, providing the liver ap-
pears histologically normal and there is no evidence 
of active hepatitis in the donor using standard bio-
chemical parameters. Two large studies in blood do-
nors are consistent with this position and have 
shown an absence of hepatitis C in recipients of 
blood obtained from donors who are anti-Hey posi-
tive but have no liver disease when biopsied.25,26 In 
contrast, both of these studies showed a very high 
rate of HCV transmission to recipients of blood ob-
tained from HCV antibody positive donors with histo-
logic evidence of liver disease. Therefore, it is sug-
gested that a histological examination of a donor 
liver with a frozen section may be the best screening 
technique presently available for general use in se-
lecting or rejecting a donor organ obtained from an 
anti-HCV positive donor. The use of PCR to detect 
HCV-RNA in serum and liver in the future should 
allow for the elimination of all donor livers contain-
ing replicating HCV. 
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